HTG Molecular Diagnostics Stock Forecast, Price & News

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for HTG Molecular Diagnostics in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" HTG Molecular Diagnostics stock.
View analyst ratings for HTG Molecular Diagnostics or view top-rated stocks.

Wall Street analysts have given HTG Molecular Diagnostics a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but HTG Molecular Diagnostics wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

HTG Molecular Diagnostics saw a increase in short interest in May. As of May 28th, there was short interest totaling 224,700 shares, an increase of 33.7% from the May 13th total of 168,100 shares. Based on an average daily trading volume, of 101,900 shares, the short-interest ratio is presently 2.2 days. Currently, 3.9% of the company's stock are sold short.
View HTG Molecular Diagnostics' Short Interest.

HTG Molecular Diagnostics is scheduled to release its next quarterly earnings announcement on Tuesday, August 10th 2021.
View our earnings forecast for HTG Molecular Diagnostics.

HTG Molecular Diagnostics, Inc. (NASDAQ:HTGM) announced its earnings results on Thursday, May, 13th. The medical research company reported ($0.80) EPS for the quarter, topping the consensus estimate of ($0.95) by $0.15. The medical research company earned $1.44 million during the quarter, compared to the consensus estimate of $1.40 million. HTG Molecular Diagnostics had a negative net margin of 261.44% and a negative trailing twelve-month return on equity of 120.05%.
View HTG Molecular Diagnostics' earnings history.

HTG Molecular Diagnostics' stock was trading at $0.3942 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, HTGM stock has increased by 1,206.4% and is now trading at $5.15.
View which stocks have been most impacted by COVID-19.

HTG Molecular Diagnostics issued an update on its first quarter 2021 earnings guidance on Tuesday, May, 4th. The company provided earnings per share (EPS) guidance of - for the period. The company issued revenue guidance of $1.40 million-$1.40 million, compared to the consensus revenue estimate of $2.39 million.

2 brokers have issued 12 month price objectives for HTG Molecular Diagnostics' stock. Their forecasts range from $9.00 to $10.00. On average, they anticipate HTG Molecular Diagnostics' share price to reach $9.50 in the next twelve months. This suggests a possible upside of 84.5% from the stock's current price.
View analysts' price targets for HTG Molecular Diagnostics or view top-rated stocks among Wall Street analysts.

11 employees have rated HTG Molecular Diagnostics CEO Tim (TJ) Johnson on Glassdoor.com. Tim (TJ) Johnson has an approval rating of 47% among HTG Molecular Diagnostics' employees. This puts Tim (TJ) Johnson in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

Some companies that are related to HTG Molecular Diagnostics include Precipio (PRPO), Astrotech (ASTC), Scientific Industries (SCND), BioForce Nanosciences (BFNH), Pressure BioSciences (PBIO), Arrayit (ARYC), DiaSys (DYXC), Orthometrix (OMRX) and PositiveID (PSID).
View all of HTGM's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other HTG Molecular Diagnostics investors own include Idera Pharmaceuticals (IDRA), Biocept (BIOC), Rigel Pharmaceuticals (RIGL), Heat Biologics (HTBX), MEI Pharma (MEIP), Zosano Pharma (ZSAN), Verastem (VSTM), Aurinia Pharmaceuticals (AUPH), Dynavax Technologies (DVAX) and Gilead Sciences (GILD).

(HTGM) raised $50 million in an initial public offering (IPO) on Wednesday, May 6th 2015. The company issued 3,600,000 shares at $13.00-$15.00 per share. Leerink Partners served as the underwriter for the IPO and Canaccord Genuity and JMP Securities were co-managers.

HTG Molecular Diagnostics trades on the NASDAQ under the ticker symbol "HTGM."

HTG Molecular Diagnostics' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Cowen Prime Services LLC (8.43%), Samjo Capital LLC (6.92%), Blue Water Life Science Advisors LLC (2.40%), Renaissance Technologies LLC (2.23%), Worth Venture Partners LLC (0.88%) and Citadel Advisors LLC (0.30%).
View institutional ownership trends for HTG Molecular Diagnostics.

HTGM stock was bought by a variety of institutional investors in the last quarter, including Blue Water Life Science Advisors LLC, Cowen Prime Services LLC, Worth Venture Partners LLC, Samjo Capital LLC, Renaissance Technologies LLC, Citadel Advisors LLC, and Citadel Advisors LLC.
View insider buying and selling activity for HTG Molecular Diagnostics or or view top insider-buying stocks.

Shares of HTGM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of HTGM stock can currently be purchased for approximately $5.15.

HTG Molecular Diagnostics has a market capitalization of $32.31 million and generates $8.55 million in revenue each year. The medical research company earns $-20,870,000.00 in net income (profit) each year or ($4.42) on an earnings per share basis.

HTG Molecular Diagnostics employs 83 workers across the globe.

The official website for HTG Molecular Diagnostics is www.htgmolecular.com.

HTG Molecular Diagnostics is headquartered at 3430 E. GLOBAL LOOP, TUCSON AZ, 85706.

HTG Molecular Diagnostics' mailing address is 3430 E. GLOBAL LOOP, TUCSON AZ, 85706. The medical research company can be reached via phone at 877-289-2615.